| NCT03225625 | Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study | MD Stem Cells | | - Age ≥ 18 yrs
- Level C1-S5
AIS A, B, C, D- ≤ 0 hours
| By invitation | 40 | NA | Biological/cell based | General health | | | 01 July 2017 | 21 July 2017 | 2 | |
| NCT03187795 | Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury | Kessler Foundation | | - Age 18 - 70 yrs
- Level C1-T11
AIS A, B, C, D- ≥ 12 months
| | 62 | PHASE2 | Drug | Bladder health/function | | | 03 April 2019 | 15 June 2017 | 1 | |
| NCT03179475 | Targin® for Chronic Pain Management in Patients With Spinal Cord Injury | University of British Columbia | | - Age 18 - 65 yrs
- Level C1-S5
AIS A, B, C, D- 3 months - 65 years
| Ended | 1 | PHASE4 | Drug | Pain | | | 05 September 2019 | 07 June 2017 | 1 | |
| NCT03139344 | Long Duration Activity and Metabolic Control After Spinal Cord Injury | University of Iowa | | - Age ≥ 18 yrs
- Level C1-S5
AIS A, B- ≥ 0 hours
| Ended | 89 | NA | Rehabilitation | General health | | | 01 August 2015 | 03 May 2017 | 1 | |
| NCT03029442 | The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury | James J. Peters Veterans Affairs Medical Center | | - Age 18 - 65 yrs
- Level C1-S5
AIS C, D- ≤ 6 months
| Ended | 5 | PHASE4 | Drug | Bone health | | | 01 April 2017 | 24 January 2017 | 3 | |
| NCT02946424 | Simvastatin to Prevent SCI-Induced Bone Loss | Craig Hospital | | - Age 18 - 60 yrs
- Level C1-S5
AIS A, B, C- ≤ 3 months
| | 76 | PHASE2 | Drug | Bone health | | | 01 July 2017 | 27 October 2016 | 1 | |
